Sep. 6, 2013, 2:02 PM
- Mettler-Toledo International (MTD +2.6%) gains after Morgan Stanley initiated the shares on valuation with an Overweight rating and a $271 price target.
- Morgan says the stock has lagged as growth disappointed on China and global macro weakness, but with growth set to improve in 2014, it sees current levels as a good entry point.
- The company has strong pricing power and a dominant, scale advantaged franchise that is superior to most peers. This, coupled with an appealing capital deployment strategy, should enable the company to achieve steady share gains.
May 7, 2013, 10:27 AM
Mettler-Toledo (MTD -1.2%) slips this morning after Jefferies cut the shares to Hold on valuation and lowered its price target to $225 from $250 following a change in coverage. The firm says the stock is already trading at a 15% premium to its peers and expectations for improved fundamentals in H213 and FY14 have already been 'baked-in' to the stock.| May 7, 2013, 10:27 AM
Apr. 11, 2013, 10:03 AM
Goldman upgrades the Life Sciences Tools & Diagnostics sector to Attractive, but some individual names suffered as Mettler Toledo (MTD -2%) and Sigma-Aldrich (SIAL -1.1%) catch downgrades to Neutral from Buy. SIAL has "few levers to drive EBIT [as] long-term organic growth guidance of 4-6% is too high." Quest Diagnostics (DGX +3.5%) and LabCorp (LH +2%) are upgraded to Buy and Neutral respectively on the former's "untapped capital allocation potential and margin expansion" and the latter's ability to manage pricing pressure.| Apr. 11, 2013, 10:03 AM
Jul. 26, 2012, 7:57 PMMettler-Toledo (MTD): Q2 EPS of $2.15 in-line. Revenue of $570.3M (+1.6% Y/Y) beats by $0.M. Shares -0.7% AH. (PR) | Jul. 26, 2012, 7:57 PM